Insigneo Advisory Services LLC Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Insigneo Advisory Services LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, Holdings Channel reports. The firm bought 552 shares of the company’s stock, valued at approximately $296,000.

A number of other institutional investors have also modified their holdings of IDXX. Global Retirement Partners LLC purchased a new position in IDEXX Laboratories in the 2nd quarter valued at $238,000. Jefferies Financial Group Inc. lifted its stake in shares of IDEXX Laboratories by 10.7% in the 2nd quarter. Jefferies Financial Group Inc. now owns 21,638 shares of the company’s stock worth $11,605,000 after acquiring an additional 2,099 shares during the period. Waterloo Capital L.P. purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at about $237,000. Prudential Financial Inc. increased its stake in shares of IDEXX Laboratories by 48.7% during the second quarter. Prudential Financial Inc. now owns 63,121 shares of the company’s stock worth $33,854,000 after acquiring an additional 20,670 shares during the period. Finally, Segall Bryant & Hamill LLC raised its holdings in IDEXX Laboratories by 11.3% during the second quarter. Segall Bryant & Hamill LLC now owns 21,086 shares of the company’s stock worth $11,309,000 after purchasing an additional 2,140 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $755.96 on Thursday. The stock has a fifty day moving average price of $663.01 and a 200 day moving average price of $602.29. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The stock has a market cap of $60.36 billion, a PE ratio of 62.94, a P/E/G ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the business posted $2.80 earnings per share. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.98% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on IDXX shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Weiss Ratings restated a “hold (c+)” rating on shares of IDEXX Laboratories in a research note on Tuesday. BTIG Research upped their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. Finally, UBS Group boosted their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $730.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.